Conjugation of RBCEVs with α‐EGFR VHH also increased the percentage of CFSE‐positive tumour cells to ∼20% in the targeted α‐EGFR‐RBCEV treatment (Figure 8c). The gene discussed is EGFR; the disease is neoplasm.